Core Insights - Lifeward Ltd. has received prior authorization from Humana Medicare Advantage Plan for its ReWalk 7 Personal Exoskeleton, marking a significant step in expanding access to innovative medical technology for individuals with spinal cord injuries [1][2][3] - Humana and UnitedHealthcare, the two largest Medicare Advantage providers in the U.S., now account for 47% of all Medicare Advantage enrollees eligible for reimbursement for the ReWalk 7 [1][3] Company Developments - The approval from Humana is expected to enhance Lifeward's revenue and cash flow dynamics, providing a clearer foundation for scalable growth in the U.S. market [1][3] - Lifeward has been actively submitting claims for reimbursement under both traditional Medicare and Medicare Advantage Plans since the Centers for Medicare & Medicaid Services (CMS) implemented a formal reimbursement pathway for personal exoskeletons in 2024 [3] Industry Context - The approval of coverage for the ReWalk 7 under Humana's Medicare Advantage Plan reflects a broader trend of increasing acceptance of innovative medical technologies within the healthcare system [2][3] - Nearly half of all Medicare Advantage enrollees are now eligible for prior authorization and reimbursement for the ReWalk 7, indicating a growing recognition of the clinical and functional value of personal exoskeleton technology [3]

This story was originally published on MedTech Dive. To receive daily news and insights, subscribe to our free daily MedTech Dive newsletter. Dive Brief: The medtech industry is approaching 2026 in an improving position, with investors increasingly optimistic and funding rebounding, PitchBook said in its outlook for next year. PitchBook analysts said strategic investors are targeting companies that are approaching clinical milestones in cardiology, orthopedics and diagnostics. The analysts named neurost ...

Summary of MedTech Industry Outlook for 2026 Industry Overview - The MedTech industry is experiencing increased stock-specific volatility and performance dispersion, which is expected to continue into 2026 [1][3][20] - Major product cycles and a supportive hospital spending environment, combined with trough valuations compared to the S&P, create a favorable setup for the industry [1][3] Key Insights - **Growth Projections**: Organic growth is estimated at +6-7% driven by innovation cycles in large markets such as concomitant PFA/LAA, RDN, TMTT, leadless pacing, and diabetes devices [3][8] - **Margin Improvement**: Margins are expected to improve due to a favorable mix shift and normalized cost/pricing dynamics [3][8] - **Hospital Spending**: Capital spending in hospitals is projected to grow by +4.1% in 2026, consistent with the previous year's growth of +4.0% [4][62] - **Reimbursement Challenges**: 34% of hospital executives cited reimbursement as the biggest challenge for the upcoming year, an increase from 25% the previous year, indicating potential shifts to lower acuity settings [3][70] Market Dynamics - **Volatility and Stock Picking**: The high degree of volatility, particularly around earnings, has made stock picking challenging and is likely to persist into 2026 [3][9] - **Investment Sentiment**: Despite macroeconomic uncertainties, hospitals are still inclined to invest in new equipment, with over 70% of hospitals considering purchases across various categories [66][70] Competitive Landscape - **Robotic Systems**: There is a notable emphasis on robotic systems in capital budgets, with companies like ISRG and SYK gaining traction in the robotics market [9][10] - **Emerging Technologies**: New growth verticals such as Renal Denervation and next-gen Neuromodulation are expected to contribute to future growth [38] Analyst Ratings and Recommendations - **Upgrades**: Companies like DexCom (DXCM) and Bausch + Lomb (BLCO) have been upgraded to Overweight due to strong operational recovery and promising pipelines [11][12] - **Cautions**: Inspire Medical Systems (INSP) has been downgraded to Equal-weight due to slowing growth and increased competition [12][14] Conclusion - The MedTech industry is positioned for growth in 2026, supported by favorable hospital spending trends and innovation in product offerings. However, challenges such as reimbursement pressures and market volatility remain significant factors to monitor [3][10][75]

PresentationAdam MaederPiper Sandler & Co., Research Division All right. We're live here, so we're going to get going. Welcome to the 2025 Piper Sandler Healthcare Conference. My name is Adam Maeder. I'm one of the Med Tech analyst here at Piper. Very pleased to introduce the team from Inspire Medical. With us, we have Tim Herbert, Chairman and CEO; and Ezgi Yagci, from Investor Relations. Thanks so much for joining us. ...

Axogen (NasdaqCM:AXGN) FY Conference Summary Company Overview - **Company**: Axogen - **Industry**: Medical Technology, specifically focused on peripheral nerve repair Core Points and Arguments 1. **Mission and Purpose**: Axogen aims to restore peripheral nerve function as a standard of care, improving health and quality of life for patients [2][4][12] 2. **Market Opportunity**: The company identifies a significant untapped market in nerve repair, particularly in extremities, breast, oral maxillofacial (OMF), head and neck, and prostate procedures [5][6][12] 3. **Current Business Model**: Axogen's business is currently domestic, with plans to expand globally, addressing a worldwide health condition [6][12] 4. **Causes of Nerve Injuries**: Nerve injuries primarily result from accidents, iatrogenic injuries during other procedures, and chronic diseases [6][7][8] 5. **Product Offerings**: Axogen has developed tools and algorithms for nerve repair, including connection, protection, and termination products, with a unique human allograft product called Avance [9][10][11] 6. **Awareness and Training**: The company is focused on raising awareness and providing training to healthcare providers to improve nerve repair procedures [12][18] 7. **Elective Procedures**: Axogen is targeting elective procedures in breast cancer, OMF, and prostate surgeries, where there is a high potential for benefit versus risk [13][14][18] 8. **Growth Expectations**: Axogen aims for 15%-20% year-on-year growth, with continuous improvements in gross margin and profitability, funded through organic cash flow [26][27] Additional Important Content 1. **Regulatory Progress**: Axogen is transitioning from a device-regulated product to a biological licensed product, with expected completion soon [21] 2. **Insurance Coverage**: The company currently enjoys about 64% coverage through commercial insurance and aims to close the gap to full coverage [22] 3. **Recent Developments**: CMS has introduced new payment changes, enhancing reimbursement for nerve repair, which is expected to facilitate broader care applications [23] 4. **Research and Evidence**: Over 70% of nerve repair literature has been published in the last five years, with more than 300 peer-reviewed publications related to Axogen products [25] 5. **Strategic Planning**: Axogen has established a strategic plan to guide its market development and product offerings, emphasizing the importance of establishing standard care practices [19][26] This summary encapsulates the key insights from the Axogen FY Conference, highlighting the company's strategic direction, market opportunities, and commitment to improving patient outcomes through innovative nerve repair solutions.

Question-and-Answer SessionI guess maybe we can start just high level. You guys just reported last month. There's been a lot of noise in tools land on the positive side, which is nice in terms of some of the pharma conversation. Maybe just give us a lay of the land in terms of how you're feeling at the moment coming out of 3Q. Again, what the right way to think about some of the pharma news is and then what it might mean to you?Prahlad SinghCEO, President & Director Sure, Patrick. Thanks for the invite. It' ...

MESA, ARIZONA / ACCESS Newswire / December 2, 2025 / Medical Care Technologies Inc. (OTC PINK:MDCE) announced today that the company is expanding its development efforts into a new generation of consumer-grade AI pre-health screening mobile applications designed to help identify early warning signs of serious health conditions and encourage timely medical intervention. This initiative builds upon MDCE's previously announced breakthrough in early melanoma detection. ...

VANCOUVER, British Columbia, Dec. 02, 2025 (GLOBE NEWSWIRE) -- Cannabix Technologies Inc. (CSE: BLO) (OTCID: BLOZF) (Frankfurt: 8CT) (the “Company or Cannabix”) developer of marijuana and alcohol breath devices is pleased to announce that it has entered into a second sales agreement for its BreathLogix unmanned alcohol screening technology with an existing European maritime shipping customer. Under this agreement, the Company will deliver an additional BreathLogix unit to enhance operational safety among cr ...

Core Insights - Integra LifeSciences Holdings Corporation, a prominent global medical technology company, will have its CEO Mojdeh Poul and CFO Lea Knight present at the Citi 2025 Global Healthcare Conference on December 3, 2025 [1] Company Overview - Integra LifeSciences is focused on restoring patients' lives through innovative treatment pathways that enhance patient outcomes and establish new standards in surgical, neurologic, and regenerative care [2] - The company offers a comprehensive portfolio of high-quality, leading brands in the medical technology sector [2]

Core Insights - BrainsWay is focused on transforming innovative medical technology into scalable business solutions that improve patient outcomes in mental health [2]. Group 1: Company Overview - The CEO of BrainsWay, Hadar Levy, has over 25 years of experience in the med tech industry, emphasizing innovation and scalability [2]. - BrainsWay is collaborating with key partners in the mental health sector, including Dr. Owen Muir, who is instrumental in addressing unmet needs in mental health and has contributed to the development of accelerated treatment protocols in the U.S. [3]. - The company has made a strategic minority investment in Stella, a rapidly growing mental health network, to enhance care delivery [4]. Group 2: Industry Context - The event highlights the increasing focus on mental health and the need for innovative solutions to provide faster relief to patients [3][4]. - The collaboration with leading clinicians and mental health networks indicates a trend towards integrated care models in the mental health industry [4].